EUVIMEDEUVIMED entdecken
Crossref

Epidermal Growth Factor Receptor as a Radiotheranostic Target in Orthotopic Models of Hepatocellular Carcinoma

Woonghee Lee, A Paden King, Kwamena Baidoo, Stephen Adler, Joon-Yong Chung, Divya Nambiar, Stanley Fayn, Orit Jacobson, Peter L Choyke, Freddy E Escorcia

Journal of Nuclear Medicine · 05.11.2026 · jnumed.126.273015

DOI: 10.2967/jnumed.126.273015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 05.11.2026. Verfasst von Woonghee Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with a 5-y survival rate of approximately 20%. Although glypican-3-targeted radiotheranostics are under development, a plurality of patients with HCC lack glypican-3 expression, underscoring the need for alternative targetable antigens. Epidermal growth factor receptor (EGFR) is overexpressed in 50%-70% of HCC tumors and represents a clinically validated therapeutic target. Here, we developed and evaluated a panitumumab-based EGFR-targeted radiotheranostic pair, [89Zr]Zr-desferrioxamine-panitumumab ([89Zr]Zr-Pani) for immuno-PET and [225Ac]Ac-Macropa-panitumumab ([225Ac]Ac-Pani) for targeted α-particle therapy, in clinically relevant orthotopic HCC models. Methods: Panitumumab was conjugated with desferrioxamine or Macropa chelators and radiolabeled with 89Zr or 225Ac, respectively. EGFR expression was characterized across a panel of HCC cell lines. Binding affinity, biodistribution, and tumor specificity were assessed in subcutaneous and orthotopic Huh-7 models, with EGFR-mediated targeting confirmed by blocking (200-fold molar excess of unlabeled panitumumab). Therapeutic efficacy was evaluated in mice bearing orthotopic Huh-7-Luc+ tumors (n = 6 per group) after a single 9.3 kBq dose of [225Ac]Ac-Pani, with longitudinal monitoring by bioluminescence imaging, [89Zr]Zr-Pani immuno-PET, and blood chemistry. Results: [89Zr]Zr-Pani exhibited high-affinity binding to EGFR (dissociation constant, 0.35 nM) and demonstrated robust tumor accumulation in both subcutaneous Huh-7 (20.6 ± 2.6 %IA/g) and orthotopic Huh-7-Luc+ tumors (19.3 ± 2.0 %IA/g) at 120-192 h postinjection. Biodistribution of [225Ac]Ac-Pani closely mirrored that of [89Zr]Zr-Pani across organs and tumors, with tumor uptake reduced approximately 5-fold by blocking (21.7 ± 1.1 vs. 4.5 ± 0.6 %IA/g; P < 0.0001), confirming EGFR-specific targeting. A single 9.3 kBq administration of [225Ac]Ac-Pani induced substantial early tumor regression and significantly prolonged median survival (70 d) compared with vehicle (28 d) and blocking (35 d) groups (log-rank P < 0.0001), with no clinically meaningful hepatotoxicity or renal toxicity. However, tumor regrowth eventually occurred in all treated mice. Conclusion: [89Zr]Zr-Pani and [225Ac]Ac-Pani represent a radiotheranostic pair that enables EGFR-specific imaging and targeted α-particle therapy in orthotopic HCC models. These findings establish EGFR as a promising radiotheranostic target in HCC, broadening the patient population eligible for image-guided radiopharmaceutical interventions for liver cancer.

Schlagwörter

Stichwörter der Autor:innen

EGFRhepatocellular carcinomaimmuno-PETradiotheranosticstargeted α-therapy

Autor:innen und Institutionen

  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; freddy.escorcia@gmail.com.
  • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and.
  • RayzeBio Inc., San Diego, California.

Zitieren

APA

Lee, W., King, A. P., Baidoo, K., Adler, S., Chung, J. Y., Nambiar, D., Fayn, S., Jacobson, O., Choyke, P. L., & Escorcia, F. E. (2026). Epidermal Growth Factor Receptor as a Radiotheranostic Target in Orthotopic Models of Hepatocellular Carcinoma. Journal of Nuclear Medicine, jnumed.126.273015. https://doi.org/10.2967/jnumed.126.273015

Vancouver

Lee W, King AP, Baidoo K, Adler S, Chung JY, Nambiar D, et al. Epidermal Growth Factor Receptor as a Radiotheranostic Target in Orthotopic Models of Hepatocellular Carcinoma. Journal of Nuclear Medicine. 2026:jnumed.126.273015. doi:10.2967/jnumed.126.273015

BibTeX
@article{Lee2026,
  author = {Lee, Woonghee and King, A Paden and Baidoo, Kwamena and Adler, Stephen and Chung, Joon-Yong and Nambiar, Divya and Fayn, Stanley and Jacobson, Orit and Choyke, Peter L and Escorcia, Freddy E},
  title = {Epidermal Growth Factor Receptor as a Radiotheranostic Target in Orthotopic Models of Hepatocellular Carcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.126.273015},
  doi = {10.2967/jnumed.126.273015}
}
Kostenlos starten →